Biat Group

What Biat Group does

Biat Group (legal entity Biotechnology Assets S.A., BME MAB ticker BST) is a Spanish publicly-listed biotechnology holding company headquartered in Jerez de la Frontera, organized around three wholly-owned operating subsidiaries: Biobide (zebrafish-based contract research organization with operations in Donostia and Boston), ZIP Solutions (proprietary SPLITTERA split-intein technology platform based in Barcelona), and Biat (biotech assets for human and animal health). The group originated from the 2017-2018 merger of Bionaturis and ADL BioPharma. The company reported €3.09M in 2025 sales with EBITDA improvement of +€1.1M and €7.7M of debt reduction over 2023-2025.

The company's commercial offering is built on two pillars. First, Biobide delivers GLP-certified aquatic ecotoxicology and toxicity testing using zebrafish embryos as a New Approach Methodology (NAM) under EU Directive 2024/1262, with OECD-compliant test batteries covering pharma, cosmetics, agrochemicals, and industrial chemicals clients (>88% mammalian concordance, 450+ substances tested annually, 20+ year track record). Second, the proprietary SPLITTERA platform — a set of four orthogonal split-intein pairs enabling site-specific protein ligation in 30 minutes with 100% specificity — underpins a family of licensing products: CLICK GENE (gene therapy, addresses viral vector size limits), CLICK BIO (antibody-drug conjugates, bispecifics, DAR control), CLICK CAR (universal switchable Split-CAR for CAR-T with CRS mitigation), CLICK VLP (virus-like particle vaccines), VACC-ZERA (DNA/RNA vaccine microparticle platform), CLICK DIAGNOSTIC (IVD kits, 50% sensitivity improvement), and CLICK'N CUT (tag-less protein purification).

Revenue mechanics combine a quote-based CRO services business (multi-year contracts, GLP-grade testing) with technology licensing and milestones (e.g., the October 2020 worldwide Splittera gene therapy license valued at €30M+). The company is enterprise-B2B focused across four primary verticals (Pharma & Biotech, Cosmetics, Agrochemical, Industrial Chemicals) with targeted use-case expansion into immunotherapy, gene therapy, and vaccine developers. Marketing relies on direct sales, the corporate website (EN/ES), and investor forums such as MedCap, rather than broad consumer channels. Patents are granted across the US, Europe, Japan, China, India, Israel, and Australia, providing global IP coverage on the SPLITTERA family.

Name

Biat Group

Legal name

Biotechnology Assets S.A.

Website

https://biatgroup.com

Company type

Public

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Biat Group is a Spanish publicly-listed biotech holding company (BME MAB: BST) operating three subsidiaries: Biobide (zebrafish NAM-based CRO services), ZIP Solutions (proprietary SPLITTERA split-intein technology platform for gene therapy, immunotherapy, vaccines, and diagnostics), and Biat (biotech assets). It serves enterprise pharma, cosmetics, agrochemical, and biotech clients globally through testing services and technology licensing.

Ownership category

akta.pro rank

Product category

Biotechnology Contract Research Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Toxicology & Safety Assessment CROs (GLP) (HLAGAAAC)

akta.pro secondary industry

Process Development & Tech Transfer (Upstream/Downstream/MSAT) (HLAGAGAE)

Keywords

• Biotechnology platforms
• Contract research services
• Protein ligation technology
• Zebrafish toxicology testing
• Technology licensing

Headquarters

HQ city

Jerez De La Frontera

HQ country

Spain

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. CRO Testing Services (Biobide): Contract research organization services providing zebrafish-based toxicity and efficacy testing to pharma, biotech, cosmetics, agrochemical, and chemical industries. GLP-certified aquatic ecotoxicology testing following OECD guidelines for regulatory submissions. Services include TERATOTOX, NEUROTOX, CARDIOTOX, HEPATOTOX, endocrine disruption screening (EASZY, RADAR, REACTIV, XETA, ZETA), and custom assay development.
2. Technology Licensing: Licensing of proprietary SPLITTERA technology platform and individual technologies (CLICK GENE, CLICK BIO, CLICK CAR, VACC-ZERA, CLICK VLP, CLICK'N CUT) for various applications including gene therapy, immunotherapy, diagnostics, and vaccine development. Worldwides license agreements with upfront payments and potential milestones/royalties.
3. VACC-ZERA Product Development: Development of proprietary vaccine products through ZIP Solutions subsidiary. VACC-ZERA-PCA1302 for prostate cancer in preclinical development. Revenue potential through product commercialization pending regulatory approval.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Biat Group develops and commercializes proprietary biotechnology assets built around the SPLITTERA split-intein protein ligation platform, delivering technology platforms for gene therapy, immunotherapy, diagnostics, vaccines, and protein purification. The group also operates Biobide, a GLP-certified contract research organization providing zebrafish-based toxicity and efficacy testing for pharma, biotech, cosmetics, agrochemical, and industrial chemical clients. Revenue is generated through CRO services and worldwide technology licensing with upfront fees, milestones, and royalties.

Product overview

Biat Group is a biotechnology corporate group with a portfolio of proprietary technology platforms and CRO services. The SPLITTERA technology platform serves as the foundation for multiple products: CLICK GENE (gene therapy), CLICK BIO (immunotherapy/bioconjugation), CLICK DIAGNOSTIC (IVD kits), CLICK VLP (vaccines), and CLICK'N CUT (protein purification). Complementing this is the VACC-ZERA DNA/RNA vaccine platform and Biobide CRO zebrafish testing services for preclinical safety and efficacy assessment. The group operates globally through subsidiaries Biobide (Donostia and Boston) and ZIP Solutions (Barcelona).

Differentiator

Problem solved

Functional benefit

Products and services

• CLICK GENE Gene therapy technology using SPLITTERA split inteins that addresses main limiting factors in gene therapy by overcoming size limitations of viral vector genes and enabling covalent reconstitution of large proteins expressed by different viral vectors in vivo. Targets biotech and pharma developers working on gene therapy delivery.
• CLICK CAR Split-CAR universal connectors for both allogeneic and autologous cells and precursors, offering multi-target capabilities (up to 4 different antigens) with built-in cytokine release syndrome (CRS) mitigation via controllable on/off connector system. Licensed to cell therapy developers in oncology.
• CLICK BIO Tailor-made functionalization platform for antibodies and antibody fragments for immunotherapy, enabling ADCs, bispecifics, companion antibodies, and therapeutic fusion proteins using SPLITTERA orthogonal split-inteins. Licensed to biopharma developers of antibody-based therapeutics.
• CLICK DIAGNOSTIC Universal in vitro diagnostic (IVD) kit manufacturing platform enabling efficient immobilization of recombinant proteins with controlled, homogeneous orientation for higher detection sensitivity in diagnostic tests. Sold/licensed to diagnostic assay manufacturers and IVD kit developers.
• CLICK VLP Split conjugation technology for creating second-generation virus-like particles (VLPs) for smart vaccines by conjugating VLPs with antigens of any size, enabling functionalization through site-specific antigen display and homogeneous results. Licensed to VLP vaccine developers.
• VACC-ZERA DNA/RNA vaccine platform that generates recombinant proteins in microparticles, particularly suited for therapeutic and prophylactic adjuvant-free vaccines. Once internalized, VACC-ZERA-antigen fusion proteins are synthesized and stored in natural microparticles. Validated in preclinical cancer and infection models showing complete tumor regression and virus clearance. Licensed to vaccine developers via ZIP Solutions.
• CLICK'N CUT Universal affinity purification system for obtaining tag-less proteins in a single step, using intein-based technology suitable for R&D, preclinical, clinical, and industrial manufacturing applications. Sold to bioprocessing and protein research laboratories.
• Biobide CRO — Zebrafish testing services Zebrafish (NAM) testing services for toxicity and efficacy assessment across pharma, cosmetics, agrochemicals, and industrial chemicals sectors. Offers GLP-certified aquatic ecotoxicology testing under OECD guidelines with assays including TERATOTOX, NEUROTOX, CARDIOTOX, HEPATOTOX, ACUTETOX, DART, EASZY, RADAR, REACTIV, XETA, ZETA, plus custom assay development. Sold as project-based CRO engagements via direct enterprise sales.

Quantifiable outcome

• 450+ substances tested annually, 2,000+ compounds tested in 5 years
• +6 more outcomes

Named customers7 records

Segments7 records

Ideal customer profiles6 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

Seven partnerships are on record, tiered major, core and minor.

• European Consortium (Vanilla Project)majorStrategic or Co-development Partner · 11 September 2023Positive resolution of European consortium project (Vanilla Project) in September 2023. EU-funded research collaboration with multiple partners.
• BSRC (Japan)coreStrategic or Co-development Partner · 25 January 2023Biobide CRO agreement with Japanese BSRC (Biomedical Sciences Testing Research Center) for zebrafish testing services. Strategic partnership expanding Biobide's presence in the Asian market and providing access to Japanese pharmaceutical clients.
• Igen Biolab GroupminorStrategic or Co-development Partner · 14 May 2020Agreement signed May 2020 for development and commercialization of products in the microbiota field. Joint product development and commercialization collaboration.
• NIH-NIEHSmajorStrategic or Co-development Partner · 1 January 2020Contract with National Institute of Environmental Health Sciences for research services. NIH collaboration provides credibility and scientific rigor to Biobide's testing methodologies.
• Japanese Pharmaceutical CompanycoreStrategic or Co-development Partner · 7 August 2019Binding collaboration agreement with major Japanese pharmaceutical company for biotech development. Long-term strategic relationship for research and development services.
• FermentalgminorStrategic or Co-development Partner · 28 September 2018Strategic agreement signed September 2018 with French biotechnology company Fermentalg for collaboration in algae-based solutions. Joint development in microalgae applications.
• Chinese and Japanese PartnersmajorChannel Partner/ Reseller/ Distributor · 2 November 2017Patent concessions granted in China and Japan to ZIP Solutions. Strategic partnerships for market access in major Asian pharmaceutical markets.

Scale indicators17 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• Lonza: A global CDMO offering biologics manufacturing and bioconjugation services. Comparable to Biat Group in the protein conjugation, purification, and biopharma manufacturing tools space.
• Evotec: A global contract research organization offering a wide range of preclinical and clinical services including zebrafish models. Operates as a broader incumbent in the CRO space where Biobide competes as a specialized player.
• Charles River Laboratories: A large global CRO offering preclinical toxicology, discovery, and manufacturing services. Comparable to Biobide as a broad incumbent providing safety assessment services though much larger and more diversified.
• WuXi AppTec: A global CRO/CDMO providing preclinical testing, biologics, and discovery services. Overlaps with Biat Group in CRO services and contract research activities across pharma and chemicals.
• Catalent: A global CDMO with bioconjugation, antibody, and cell therapy capabilities. Overlaps with Biat's CLICK BIO/CLICK CAR/CAR-T and bioconjugation platform technologies in pharma development services.
• Eurofins Discovery: A global CRO providing preclinical, toxicology, and discovery services to pharma, chemicals, and cosmetics clients. Comparable as a broad incumbent in ecotoxicology and safety testing where Biobide operates.

Direct peers

• ZeClinics: A zebrafish-focused preclinical CRO providing toxicity and efficacy testing services for pharma and chemicals. Directly comparable to Biobide in service offering, scientific positioning, and customer profile.
• Danio Lab: A zebrafish-based CRO offering toxicity and efficacy screening services to pharma and chemical companies. Closely comparable to Biobide in technology platform and go-to-market focus.

Emerging players

• NBE Therapeutics: Focused on antibody-drug conjugates with proprietary site-specific conjugation technology. Comparable to Biat's CLICK BIO platform in targeting ADC bioconjugation for oncology therapeutics.
• Heidelberg Pharma: Develops ADCs and owns proprietary payload and conjugation technology. Direct adjacency to Biat's CLICK BIO in the bioconjugation/ADC space with comparable therapeutic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/biatgroup
• LinkedInlinkedin.com/company/biat-group

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biat Group